News About: Goverment
Government Announces Fixed-Rate Medical Service Valuation
The Ministry of Health and Welfare (MOHW) announced that it plans to introduce the fixed-rate medical service valuation under the current National Health Insurance claim reimbursement provision to the domestic medical...
Insurance Coverage for Hepatitis B Medications Being Expanded
The National Health Insurance (NHI) coverage allowance on the medications for treatment of chronic hepatitis B virus (HBV) is continuously being adjusted to provide the expanded treatment opportunities for the domesti...
180 Drugs Newly Registered under National Health Insurance
Effective April 1st, a total of 180 drugs are to be newly registered under the National Health Insurance (NHI) list of pharmaceutical products with their applicable coverage details under both reimbursable and non-rei...
Manufacturers to Report Self-Inspection Results in May and September
The Seoul Regional Korea Food and Drug Administration (RKFDA) recently announced the current-year operational plan towards the self-imposed quality inspections, which are to be performed by the manufacturers and impor...
Incentive-Eligible Drugs for Substitution Dispensary Reach 2,357
According to the latest report released by the Health Insurance Review Agency (HIRA) on the list of incentive-eligible drugs for substitution dispensary, the total number has reached at 2,357 items as of February.
...
Cultured Epidermal Homograft Developed by Domestic Company
The Korea Food and Drug Administration (KFDA) said it has approved market authorization of Tego Science's Kaloderm, a cultured epidermal homograft (CEH) for skin replacement and wound healing, effective March 21st.
...
KFDA to Request Additional Data on Hanmi's Anti-Obesity Drug
According to an industry source, the Korea Food and Drug Administration (KFDA) is to request Hanmi Pharmaceuticals to make an additional data provision for its anti-obesity drug Slimer (active ingredient: sibutramine ...
Confirmation Made on Successive Rollout of Bioequivalence Testing Requirement
The Regulatory Reform Committee recently announced of the final recommendations generated from the extra deliberation session on the amendment proposals to the Korea Pharmaceutical Affairs Law.
Among the various dr...
KFDA Makes Joint Collaboration Agreement with Consumer Protection Board Towards Public Safety
The Korea Food and Drug Administration (KFDA) recently made a joint collaboration agreement with the Korea Consumer Protection Board (KCPB), under an initiative to jointly promote the public welfare and trust on the h...
KFDA Views Hanmi's Anti-obesity Drug Slimer as Generic Version
The Korea Food and Drug Administration (KFDA) recently expressed of its position to recognize Hanmi Pharmaceutical's anti-obesity drug Slimer as an equivalent generic version to the original drug Reductil by Abbott Ko...
